Insights On Facility Design
-
Creating Accurate, Efficient, And Effective CDMO Project Proposals
8/15/2023
To receive the most comprehensive project proposal possible, it is important to fill out any questionnaire as accurately and completely as possible.
-
Continuous Growth In Advanced Therapies
8/15/2023
As the industry continues to see innovation in manufacturing approaches, the Project Farma team discusses how advanced therapies differ from traditional medicines.
-
Cleaning Proteins, RNA, And DNA From Laboratory Equipment
8/8/2023
Learn about three of the best methods for cleaning proteins, RNA, and DNA from laboratory equipment.
-
The Case For Early Use Of cGMP Raw Materials
7/14/2023
Using cGMP grade reagents earlier makes for a seamless transition while maintaining quality and viability.
-
Modular Cleanroom Overview
7/14/2023
Gain insight into AES' projects and experience in cleanroom design innovation, manufacturing, and construction. In this overview, Avid Bioservices, INCOG BioPharma, Theragent, and Charles River share the value of partnering with AES.
-
Manual vs. Automated Labware Washing
7/7/2023
Compare manually washed labware and labware cleaned in automatic washing systems, to see how the challenges of manual washing can impact your labs efficacy and repeatability.
-
Delving Into Modular Cleanroom Designs For Drug Manufacturing
6/19/2023
Explore the reasoning behind the increasing demand for cleanroom technology as well as the advantages modular cleanroom design brings to the sterile processing of complex therapies.
-
Audience Q&A
6/7/2023
Listen in to real-time questions and answers from the audience. During “Building An In-House Cell & Gene Manufacturing Facility – Best Practices & Lessons Learned.”
-
Speed To Clinic
6/7/2023
Does or should speed to clinic impact a company’s decision to build versus buy? Explore this question and others along with lessons regarding capacity and meeting anticipated demand.
-
Building The Team
6/7/2023
When building a production line from lab-based processes, sometimes staff primarily familiar with research might not know the specifics of regulations relating to late-stage drug production.